HealWELL AI Inc

WELL Health and HEALWELL AI Expand Strategic Alliance Agreement to Develop an AI-Enhanced Clinical Trials Program to Accelerate Innovation and Improve Patient Outcomes

  • WELL Health and HEALWELL AI announce the expansion of their multi-year agreement that allows WELL and HEALWELL to launch and manage clinical trial sites at WELL Health clinic locations across Canada. Leveraging HEALWELL’s Contract Research Organization (CRO) capabilities alongside WELL Health’s network of clinics across Canada, positions the partnership as a formidable player in AI-driven clinical trials, and opens up new revenue streams.

  • This partnership allows HEALWELL AI to offer an end-to-end vertically integrated service, inclusive of: patient identification and recruitment, clinical trial architecture and execution and clinical research data analysis.

  • Providing clinical trial sites within WELL Health clinics transforms these clinics into hubs of innovation, improves accessibility and directly benefits patients by bringing experimental treatments to local sites.

  • Launching and managing clinical trial sites at WELL Health’s clinic locations across Canada would be a powerful strategic initiative. This could allow WELL Health and HEALWELL to capitalize on their combined strengths in healthcare infrastructure and AI technology, potentially transforming the landscape for clinical research.

VANCOUVER, BC and TORONTO, ON, October 29, 2024 – WELL Health Technologies Corp. (TSX: WELL; OTCQX: WHTCF) (“WELL”), a digital health company focused on tech-enabling healthcare providers, and HEALWELL AI Inc. (TSX: AIDX, OTCQX: HWAIF) (“HEALWELL”), a healthcare technology company focused on AI and data science for preventative care, are jointly pleased to announce the expansion of their multi-year strategic alliance agreement that allows WELL and HEALWELL to launch and manage clinical trial sites at WELL clinic locations across Canada. Leveraging the country’s largest network of primary and specialty care clinics, with over 180 clinics and thousands of healthcare practitioners, HEALWELL and WELL will collaborate to expand clinical trial access to more patients than ever before. By combining their strengths in healthcare infrastructure and AI technology, WELL and HEALWELL aim to transform the clinical research landscape. 

This partnership allows HEALWELL AI to offer an end-to-end vertically integrated service, from patient recruitment to trial execution and data analysis for clinical research. By including WELL Health Diagnostic Centres (WHDC) and its robust specialty care patient roster, including cardiology, radiology, sleep medicine and endocrinology, the partnership can leverage valuable patient data to enhance research, particularly in cardiovascular disease and its co-morbidities, where pharmaceutical interest is significant. For WELL, hosting trials within its clinics will transform them into hubs of innovation, directly benefitting patients by bringing experimental treatments to local sites and improving accessibility. Leveraging HEALWELL’s Contract Research Organization (CRO) capabilities alongside WELL’s clinic infrastructure positions the partnership as a formidable player in AI-driven clinical trials, fostering the potential for new revenue. 

Dr. Michael Frankel, Chief Medical Officer of WELL, commented, “Launching and managing clinical trial sites at WELL’s clinic locations across Canada is a powerful and transformational strategic initiative. This initiative will allow WELL and HEALWELL to capitalize on their combined strengths in healthcare infrastructure and AI technology, potentially transforming the landscape for clinical research.” 

Dr. Alexander Dobranowski, CEO of HEALWELL, commented, “Patient identification and recruitment for clinical trials has become an increasingly complex challenge in the global healthcare and life science sectors.  Success hinges not only on identifying patients but also on effectively recruiting them and managing their participation – steps that lead to improved outcomes for patients, practitioners and the healthcare system as a whole. Through our established late stage CRO, Canadian Phase Onward, HEALWELL has already made significant strides in accelerating the recruitment process, but the growing network of WELL clinics is an opportunity for us to execute our plans at scale. Ultimately, this service will be a benefit to doctors, healthcare practitioners and patients alike while reducing the cost of clinical trials and shortening their timelines.” 

Some strategic benefits of the partnership include: 

  • Increased Access to Clinical Trials: With WELL’s extensive and growing network of over 180 primary and specialty clinics nationwide, patients across diverse Canadian regions will have more convenient access to clinical trials. This expansive reach supports recruitment for a wide array of clinical trial programs, from common therapeutic areas to highly specialized conditions. HEALWELL focuses on recruiting niche patient populations, including those with rare diseases, specific genetic profiles, or unique demographic backgrounds. This focus improves the feasibility and inclusivity of trials, enabling sponsors to explore treatments for unmet medical needs. As a result, trials can achieve greater patient participation and gather more representative data, ultimately strengthening the value and relevance of clinical research findings.

     

  • Enhanced Efficiency with AI-Driven Solutions: HEALWELL’s focus on advanced AI and data science is expected to streamline trial processes, from patient recruitment to data analysis. AI-driven tools also help identify eligible participants, predict outcomes, and reduce trial duration by automating data collection and analysis, making the process more efficient and cost-effective.

     

  • Strengthened Position in the Healthcare Innovation Market: By establishing a unique niche in AI-enhanced clinical trials, WELL and HEALWELL position themselves as leaders in the emerging space of digital healthcare solutions for research. These efforts will enhance partnerships with pharmaceutical companies and other research institutions seeking to leverage AI for trial optimizations, contributing to financial growth and technological development.

     

  • Data-Driven Insights for Future Healthcare Innovations: Operating clinical trials at scale will generate valuable real-world data that can inform future healthcare innovations. These insights can support HEALWELL AI’s goal to enhance disease detection and preventative care tools, creating a cycle of continuous improvement that benefits both clinical outcomes and business objectives.

Hamed Shahbazi 
Chairman and Chief Executive Officer 
WELL Health Technologies Corp. 

Dr. Alexander Dobranowski 
Chief Executive Officer 
HEALWELL AI Inc. 

About WELL Health Technologies Corp.

WELL’s mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL’s comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL’s solutions enable more than 37,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 180 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL’s solutions are focused on specialized markets such as the gastrointestinal market, women’s health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol “WELL” and on the OTC Exchange under the symbol “WHTCF”. To learn more about WELL, please visit: www.well.company.   

About HEALWELL AI

HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company’s road map. HEALWELL is publicly traded on the Toronto Stock Exchange (the “TSX”) under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL, please visit https://healwell.ai/ 

Forward-Looking Statements

Certain statements in this press release, constitute “forward-looking information” and “forward looking statements” (collectively, “forward looking statements”) within the meaning of applicable Canadian securities laws, including the potential benefits of utilizing WELL’s clinic network for HEALWELL’s clinical trials. Forward-looking statements are necessarily based upon management’s perceptions of technical abilities and assumed benefits, while considered reasonable by WELL and HEALWELL as of the date of such statements, are outside of WELL and HEALWELL’s control and are inherently subject to business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to the ability to identify and recruit patients, obtaining all required government consents to conduct trials at such clinic locations, and obtaining pharmaceutical sponsor consents for the trials to be conducted at WELL’s clinics. 

Known and unknown risk factors, many of which are beyond the control of WELL and HEALWELL, could cause the actual benefits and integration plans to differ materially from the results implied by such forward-looking statements. Such risk factors include not obtaining any required government or research ethic board consents, not successfully identifying candidate patients for clinical trials, not being able to recruit interested physicians in assisting with such clinical trials, and the other risks discussed under the section entitled “Risk Factors” in WELL and HEALWELL’s most recent annual information form, which is available under the companies’ respective SEDAR+ profile at www.sedarplus.ca. The risk factors are not intended to represent a complete list of the factors that could affect WELL and HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual benefits could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. WELL and HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements. 

For more information:

Tyler Baba 
Investor Relations, Manager 
WELL Health Technologies Corp. 
Phone: 604-628-7266   
investor@well.company 

 

Pardeep S. Sangha 
Investor Relations 
HEALWELL AI Inc. 
Phone:  604-572-6392 
ir@healwell.ai 

Khure Health

Khure Health is a wholly owned subsidiary of HEALWELL AI. Khure is an AI health technology company whose precision medicine platform harnesses clinical data, enabling physicians to rapidly screen and identify patients with rare diseases and facilitate more personalized treatment.

Khure is actively working with and/or has rare and specialty disease programs in development with 6 of the top 10 pharma companies and international disease associations.
Visit Website →

This will close in 0 seconds

Pentavere

HEALWELL AI is a majority shareholder of Pentavere Research Group, a globally recognized and award-winning AI digital health company that has built a best-in-class AI engine to identify patients that are eligible for approved medications or interventions, to improve outcomes for patients and help drive therapy growth and penetration. Over the past several years, Pentavere has published an impressive array of literature in high-impact, peer-reviewed medical journals, totaling more than 30 manuscripts, which serve as a testament to Pentavere’s capabilities and adds significant credibility to their technology.
Visit Website →

This will close in 0 seconds

Intrahealth

Intrahealth is a pioneering force in healthcare technology, specializing in the development and implementation of state-of-the-art EMR solutions. With a relentless commitment to advancing patient care, Intrahealth empowers healthcare providers, institutions, and governments with innovative digital tools designed to enhance healthcare delivery and improve patient outcomes.
Visit Website →

This will close in 0 seconds

VeroSource Solutions

VeroSource Solutions is a digital health company established in 2014 to empower people and unlock the potential in Canadian healthcare. Its team of professionals has extensive experience in the full lifecycle of healthcare IT solutions and offers healthcare providers the technology and support needed to go digital. VeroSource’s cloud-first multi-channel software securely connects people, data and systems to drive digital healthcare transformation. Founded in Fredericton, NB, VeroSource has grown to include team members across Ontario and Atlantic Canadian.
Visit Website →

This will close in 0 seconds

BioPharma Services

BioPharma Services is a leading contract research organization (CRO) based in Toronto, Canada, specializing in Phase 1 and Phase 2a clinical trials. With a focus on scientific integrity, operational excellence, and adaptive processes tailored to each client’s needs, BioPharma Services has established a reputation for delivering high-quality results in the pharmaceutical and biotech industries. BioPharma’s comprehensive services also include Bioanalysis at their GLP Certified Laboratory, Scientific and Regulatory Affairs, Biostatistics and Safety Data Analysis (CDISC), Data Management and Medical Writing.
Visit Website →

This will close in 0 seconds

PolyClinic

HEALWELL AI Polyclinic provides onsite integrated health services including primary care, specialist care, lab services, and an in-house clinical research organization. With integrated systems and data-driven tools, HEALWELL AI Polyclinic plans to unlock meaningful insights from consistent, high-quality, structured clinical information from over 50 primary care physicians and specialists, labs, and clinical trials.
Visit Website →

This will close in 0 seconds

Doctorly

Founded in 2018, doctorly is a European based digital health-tech startup with a company mission of 'enabling people to live healthier lives'. With an initial focus on Europe’s largest market, Germany, doctorly has built a brand new, fully regulated practice management software to redefine how medical practices work. As an all-in-one solution, doctorly provides a fully centralised, cloud powered, GDPR compliant, medical practice operating system that dramatically reduces the time and effort doctors and medical assistants spend on day-to-day administrative tasks. doctorly is financially backed by some of the world’s most renowned venture capital firms. To learn more about doctorly please visit: www.doctorly.de

Read the original press release here.
Visit Website →

This will close in 0 seconds

xAI

xAI is a company working on building artificial intelligence to accelerate human scientific discovery. They're guided by their mission to advance our collective understanding of the universe. The team is led by Elon Musk, CEO of Tesla and SpaceX. Collectively their team has contributed some of the most widely used methods in the field, in particular the Adam optimizer, Batch Normalization, Layer Normalization, and the discovery of adversarial examples. They further introduced innovative techniques and analyses such as Transformer-XL, Autoformalization, the Memorizing Transformer, Batch Size Scaling, μTransfer, and SimCLR. They have worked on and led the development of some of the largest breakthroughs in the field including AlphaStar, AlphaCode, Inception, Minerva, GPT-3.5, and GPT-4. Learn more at https://x.ai/ Read the original press release here.
Visit Website →

This will close in 0 seconds

Mutuo Health Solutions

Mutuo Health Solutions is a Toronto-based medical artificial intelligence company focused on developing predictive clinical AI technology. Their flagship product, AutoScribe, is an advanced AI-powered ambient scribe solution that transcribes clinician-patient interactions into high-quality electronic medical records in real time. AutoScribe utilizes natural language processing and machine learning technology to accurately capture and structure patient data, enabling healthcare providers to focus on patient care and improve clinical efficiency.

Visit Website →

This will close in 0 seconds

Abstractive Health

Abstractive Health is on a mission to transform the healthcare industry by automating clinical documentation with generative AI. Their innovative AI software creates comprehensive patient summaries, streamlining workflows and empowering healthcare providers to focus on patient care. By harnessing advanced language models, the company delivers accurate, medically relevant insights directly to clinicians, enabling informed decision-making and improved patient outcomes. Read the original press release here. 

Visit Website →

This will close in 0 seconds